Ocumension Therapeutics (Ocumension) reported no changes in its authorised or issued share capital for the month ended 30 September 2026, according to the company’s latest filing with Hong Kong Exchanges and Clearing Limited.

Authorised and Issued Share Capital • Authorised share capital remained at 5.00 billion ordinary shares with a par value of USD 0.00001, representing total authorised capital of USD 50,000. • Issued shares (excluding treasury stock) stood unchanged at 815.38 million, while treasury shares were steady at 20.95 million, leaving total issued shares at 836.33 million. • No shares were issued, cancelled, or transferred from treasury during the month, resulting in zero net movement in either issued or treasury shares.

Public Float Compliance • The company confirmed compliance with the Main Board’s 25% minimum public-float requirement as of 30 September 2026.

Equity Incentive Schemes • Employee Stock Option Plan (2018): 13.32 million options remained outstanding; no grants, exercises, cancellations, or lapses occurred in September. • 2021 Share Option Scheme: Outstanding options declined by 0.26 million to 44.97 million due to lapses; no grants or exercises were recorded. The plan still allows up to 65.23 million shares to be issued upon future grants. • 2021 Share Award Scheme: Unvested awards decreased from 16.31 million to 14.80 million after 1.28 million awards vested and 0.22 million lapsed. No new shares were issued under the scheme during the month.

Capital-Raising Activity • No funds were raised via option exercises or other equity instruments in September, and the company reported no outstanding warrants or convertible securities.

Overall, Ocumension’s September 2026 report indicates a stable capital structure with no dilution events and ongoing adherence to public-float requirements, while equity incentive plans continue to be managed within approved limits.